Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in… CISION PRNewswireMay 21, 2025
Press Release Nota AI and DEEPX Sign MOU at Computex Taipei to Lead the On-Device AI Market – Merging ultra-low-power AI semiconductors with lightweight AI technology to target global… CISION PRNewswireMay 21, 2025
Press Release Lumenato™ Receives EFSA Approval, Expanding Market Availability BRANCHBURG, N.J., May 21, 2025 /PRNewswire/ — The European Food Safety Authority… CISION PRNewswireMay 21, 2025
Virtusa Bolsters Expansion Plans with Acquisition of Mav3rik Accelerating growth and scale in the Australia Region as a leader in… CISION PRNewswireMay 21, 2025
TIER IV Selects PlaxidityX to Provide Cyber Security Expertise for The Japanese Airport Autonomous Bus Project As an automotive Cyber Security Expert, PlaxidityX partners with TIER IV to… CISION PRNewswireMay 21, 2025
Press Release Air Liquide partners with Manildra Group to build Australia's largest biogenic CO₂ plant, strengthening national supply MELBOURNE, Australia, May 21, 2025 /PRNewswire/ — Air Liquide has entered into an… CISION PRNewswireMay 21, 2025
Press Release SIG SAUER Announces U.S. Army Designates Type Classification Milestone for the NGSW Lethality Program NGSW Type Classified NEWINGTON, N.H., May 21, 2025 /PRNewswire/ — SIG SAUER, industry… CISION PRNewswireMay 21, 2025
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows HELSINKI, May 21, 2025 /PRNewswire/ — New research presented today at the… CISION PRNewswireMay 21, 2025
